Wall Street Fundamentals Releases New In-Depth Stock Reports on CLSN, MNKD, NKTR and VPHM

The biotech industry’s surge in 2013 seems to have cooled in recent weeks as the sector has been hit by a broad slump in the markets. The SPDR S&P Biotech ETF (NYSEARCA: XBI) and the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) have posted declines of 3.65 and 4.04 percent in the past week. Federal Reserve Chairman Ben Bernanke’s comments hinting that bond purchases may be scaled back later this year sent markets sliding sharply this past week. Although it may not have a major effect on the Biotech sector in the long run it has made investors more susceptible to news triggering them to take gains or cut losses.

Celsion Corporation (NASDAQ: CLSN) shares traded in the range of $1.21 to $1.35 Friday on volume of 3.22 million shares traded before settling to close at $1.22, a decrease of 8.27. The stock appears to be facing strong resistance at $1.24. Shares of Celsion have gained approximately 6.2 percent in the past week.

More information on Celsion and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CLSN

MannKind Corporation (NASDAQ: MNKD) shares traded in the range of $6.26 to $6.88 Friday before settling to close at $6.72, an increase of 0.37 percent. The stock appears to be facing resistance at the $7.09 and $7.77 levels. The company expects to release data from a Phase 3 clinical study of AFREZZA in patients with type 2 diabetes later this summer. Shares of MannKind have fallen approximately 12.8 percent in the past week.

More information on MannKind and access to the free equity report can be found at:
www.WallStreetFundamentals.com/MNKD

Nektar Therapeutics (NASDAQ: NKTR) shares traded in the range of $10.50 to $11.05 Friday before settling to close at $10.99, an increase of 3.82 percent. The stock appears to be facing some resistance at $11.06 with some support at $10.48. Shares of the company have surged since reporting positive top-line results from a human abuse liability (HAL) study for NKTR-181. Shares of Nektar Therapeutics have gained approximately 18.6 percent in the past week.

More information on Nektar Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/NKTR

Viropharma Inc. (NASDAQ: VPHM) shares traded in the range of $27.72 to $28.73 Friday before settling to close at $28.23, an increase of 1.18 percent. The stock appears to be facing resistance at the $28.54 and $28.86 levels. According to a recent Reuters article, the company “is attracting preliminary acquisition interest from several pharmaceutical companies”. Shares of Viropharma have gained approximately 3.95 percent in the past week.

More information on Viropharma and access to the free equity report can be found at:
www.WallStreetFundamentals.com/VPHM

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com